Search the Community

Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis. Corbus Pharmaceuticals announced today that the Company will proceed with a Phase 3 trial evaluating the efficacy and safety of lenabasum for the treatment of dermatomyositis. Globe Newswire, 07/25/2018. (Also see Treatments for Dermatomyositis, Endocannabinoid System and Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. As in adults with inclusion body myositis, patients with juvenile myositis with anti-NT5C1A autoantibodies have more severe disease. PubMed, Ann rheumatologist Dis, 2018 May;77(5):714-719. (Also see Dermatomyositis and Polymyositis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Muscle biopsy in combination with myositis–specific autoantibodies aids prediction of outcomes in juvenile dermatomyositis. Muscle pathology, in combination with MSA, predicts the risk of remaining on treatment in JDM and may be useful for discussing probable treatment length with parents and patients. PubMed, Arthritis Rheumatol, 05/23/2016. (Also see Dermatomyositis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.